Диссертация (1154305), страница 31
Текст из файла (страница 31)
Yazawa, Y. Yamamoto, T. Takahashi, Y.Takahashi, K. Imai, S. Koyama, Y. Inoue, D. Tsuji, H. Hayashi, K. Itoh // TherDrug Monit. – 2014. – Vol. 36. – № 3. – P. 406-409.173.Jallon, P. ILAE workshop report: Epilepsy in developing countries / P. Jallon// Epilepsia. – 1997. – Vol. 38, № 10. – P. 1143–1151.174.Jannuzzi, G. A multicenter randomized controlled trial on the clinical impactof therapeutic drug monitoring in patients with newly diagnosed epilepsy. TheItalian TDM Study Group in Epilepsy / G. Jannuzzi, P.
Cian, C. Fattore, G. Gatti,A. Bartoli, F. Monaco, E. Perucca // Epilepsia. – 2000 Feb;41(2):222-30.175.Johnson, J.A. Drug-related morbidityand mortality: A cost-of-illness model/ J.A. Johnson, J.L. Bootman // Archives of Internal Medicine. – 1995. – Vol. 155.– P.1949-1956.176.Jong, G.W. Survey of the use of off- label and unlicensed drugs in a dutchchildrens hospital / G.W. Jong, A.G. Vulto,M. de Hoog, K.J.
Schimmel, D.Tibboel, J.N.A. van Den Anker // Pediatrics. – 2001;108:1089-1093.177.Ju, С. Mechanism of idiosyncratic drug reactions: reactive metaboliteformation, protein binding and the regulation of the immune system / C. Ju, J.P.Uetrecht // Curr. Drug Metab.
– 2002. – Vol. 3, № 4. – P. 367-377.178.Jung, J. The economic burden of epilepsy in Korea, 2010 / J. Jung, H.Y. Seo,Y.A. Kim, I.H. Oh, Y.H. Lee, S.J. Yoon // J Prev Med Public Health. – 2013 Nov;46(6):293-299.179.Kale, R. Global campaign against epilepsy: the treatment gap / R. Kale //Epilepsia. – 2002. – Vol. 43. – № 6. – P. 31-33.180.Kiang, T.K. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproicacid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1genotype / T.K. Kiang, P.C. Ho, M.R. Anari, et al. // Toxicol.
Sci. – 2006 Dec. –Vol. 94. – № 2. – P. 261-271.188181.Korístková, B. Comparison of the consumption of antiepileptic drugs in theCzech Republic, Scandinavia, and Australia / B. Korístková, M. Grundmann //Ceska Slov. Farm. – 2005 May. – Vol. 54. – № 3. – P. 130-136.182.Kotsopoulos, I.A.W. Systematic review and meta-analysis of incidencestudies of epilepsy and unprovoked seizures / I.A.W. Kotsopoulos, T. van Merode,F.G. Kessels [et al.] // Epilepsia. – 2002. – Vol. 43. – P.
1402-1409.183.Kousar, S. Clinical relevance of genetic polymorphism in CYP2C9 gene topharmacodynamics and pharmacokinetics of phenytoin in epileptic patients:validatory pharmacogenomic approach to pharmacovigilance / S. Kousar, Z.A.Wafai, M.A. Wani, T.R. Jan, K.I. Andrabi // Int J Clin Pharmacol Ther. – 2015. –Jul;53(7):504-516.184.Krishnamoorthy, G. Early predisposition to osteomalacia in Indian adults onphenytoin or valproate monotherapy and effective prophylaxis by simultaneoussupplementation with calcium and 25-hydroxy vitamin D at recommended dailyallowance dosage: a prospective study / G. Krishnamoorthy, R. Nair, U.
Sundar, P.Kini, M. Shrivastava // Neurol India. – 2010;58:213-219.185.Krishnan, A. Cost of epilepsy in patients attending a secondary-level hospitalin India / A. Krishnan, S.U. Sahariah, S.K. Kapoor // Epilepsia. – 2004 Mar. – Vol.45. – № 3. – P. 289-291.186.Lazarou, J. Incidence of adverse drug reactions in hospitalized patients / J.Lazarou, B.H. Pomeranz, P.N. Corey // JAMA. – 1998. – Vol. 279. – P.1200-1205.187.Leidy, N.K.
Seizure frequency and the health-related quality of life of adultswith epilepsy / N.K. Leidy, B.V. Elixhauser, E. Means, M.K. Willian // Neurology.– 1999;53:162-166.188.Li, H. The roles of variants in human multidrug resistance (MDR1) gene andtheir haplotypes on antiepileptic drugs response: a meta-analysis of 57 studies / H.Li, B. Wang, C. Chang, M. Wu, Y. Xu, Y.
Jiang // PLoSOne. – 2015 Mar27;10(3):e0122043.189189.Liu, J. The economic burden of epilepsy in a sample of people with epilepsyin China / J. Liu, Z. Liu, F. Meng // Epilepsy Res. – 2013 Feb;103(2-3):288-93.190.Löscher, W. The clinical impact of pharmacogenetics on the treatment ofepilepsy / W. Löscher, U. Klotz, F. Zimprich, D. Schmidt // Epilepsia. – 2009Jan;50(1):1-23.191.LoVecchio, F. L-carnitine was safely administered in the setting of valproatetoxicity / F. LoVecchio, J.
Shriki, R. Samaddar // Am. J. Emerg. Med. – 2005. –Vol. 23, № 3. – P. 321-322.192.Lucas, P.T. An epilepsy mutation in the beta1 subunit of the voltage-gatedsodium channel results in reduced channel sensitivity to phenytoin / P.T. Lucas,L.S. Meadows, J. Nicholls, D.S. Ragsdale // Epilepsy Res. – 2005 May. – Vol. 64.– № 3. – P. 77-84.193.Mac, T.L.
Epidemiology, aetiology, and clinical management of epilepsy inAsia: a systematic review / T.L. Mac, D.S. Tran, F. Quet [et al.] // Lancet Neurol.– 2007. – Vol. 6. – P. 533-543.194.Malerba, A. Patterns of prescription of antiepileptic drugs in patients withrefractory epilepsy at tertiary referral centres in Italy / A. Malerba, C. Ciampa, S.De Fazio, C. Fattore, B. Frassine, A. La Neve, S. Pellacani, L.M. Specchio, A.Tiberti, P. Tinuper, E. Perucca // Epilepsy Res.
– 2010 Oct;91(2-3):273-82. doi:10.1016/j.eplepsyres.2010.08.002.195.McHugh, J.C. Epidemiology and classification of epilepsy: gendercomparisons / J.C. McHugh, N. Delanty // Int. Rev. Neurobiol. – 2008. – Vol. 83.– P. 11-26.196.McLernon, D.J. Adverse drug reaction reporting in the UK: a retrospectiveobservational comparison of yellow card reports submitted by patients andhealthcare professionals / D.J. McLernon, C.M. Bond, P.C. Hannaford, M.C.Watson, A.J.
Lee, L. Hazell, A. Avery // DrugSaf. – 2010 Sep 1;33(9):775-88.197.Mojumder, D.K. Differential ammonia decay kinetics indicates more thanone concurrent etiological mechanism for symptomatic hyperammonemia caused190by valproate overdose / D.K. Mojumder, R.R. De Oleo // Indian J. Pharmacol. –2014 May-Jun. – Vol. 46. – № 3. – P. 345-347. doi: 10.4103/0253-7613.132200.198.Morceau, F.
Molecular and Therapeutic Potential and Toxicity of ValproicAcid / F. Morceau, M. Dicato, M. Diederich // J. Biomed. Biotechnol. – 2010.2010: 479364. doi: 10.1155/2010/479364199.Mulhern, B. The development of a QALY measure for epilepsy: NEWQOL-6D / B. Mulhern, D. Rowen, A. Jacoby, T.
Marson, D. Snape, D. Hughes, N.Latimer, G.A. Baker, J.E. Brazier // EpilepsyBehav. – 2012 May;24(1):36-43.200.Naranjo, C.A. A method for estimating the probability of adverse drugreactions / C.A. Naranjo, U. Busto, E.M. Sellers, P. Sandor, I. Ruiz, E.A. Roberts,E. Janecek, C.
Domecq, D.J. Greenblatt // Clin. Pharmacol. Ther. – 1981. – Vol.30. – № 2. – P. 239-245.201.M.G.Nanau, R.M. Adverse drug reactions induced by valproic acid / R.M. Nanau,Neuman//ClinBiochem.–2013Oct;46(15):1323-38.doi:10.1016/j.clinbiochem.2013.06.012.202.Nevitt, S.J. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data / S.J. Nevitt, M. Sudell, J. Weston, C. TudurSmith, A.G. Marson // Cochrane Database Syst. Rev.
– 2017 Jun 29;6:CD011412.doi: 10.1002/14651858.CD011412.pub2.203.Nidanapu, R.P. Comparative Effect of Divided Doses of Adult Solid andLiquid Oral Formulations of Antiepileptic Drugs in the Management of PediatricEpilepsy / R.P. Nidanapu, B. Tamijarassy, S. Mahadevan, B. Gitanjali // J.Pharmacol. Pharmacother.
– 2017 Apr-Jun;8(2). – P. 54-61.204.Nolan, S.J. Carbamazepine versus phenobarbitone monotherapy forepilepsy: an individual participant data review / S.J. Nolan, A.G. Marson, J.Weston, C. Tudur Smith // Cochrane Database Syst Rev. – 2016 Dec15;12:CD001904. doi: 10.1002/14651858.CD001904.pub3..205.Oros, M.M. Pharmacogenetic criteria of drug-resistant epilepsy / M.M. Oros// Lik Sprava. – 2012. – Dec;(8). – P.71-74.191206.Ortega-Vázquez, A. CYP2C9, CYP2C19, ABCB1 genetic polymorphismsand phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy /A.
Ortega-Vázquez, P. Dorado, I. Fricke-Galindo, H. Jung-Cook, N. MonroyJaramillo, I.E. Martínez-Juárez, I. Familiar-López, E. Peñas-Lledó, A. Lerena, M.López-López // Pharmacogenomics J. – 2016 Jun;16(3):286-292.207.Oteri, A. Prescribing pattern of anti-epileptic drugs in an Italian setting ofelderly outpatients: a population-based study during 2004-07 / A. Oteri, G. Trifirò,M.S.
Gagliostro, D.U. Tari, S. Moretti, P. Bramanti, E. Spina, A.P. Caputi, V.Arcoraci // Br J Clin Pharmacol. – 2010 Oct;70(4):514-522. doi: 10.1111/j.13652125.2010.03619.x.208.Palčevski, G. Unlicensed and off-label drug use in hospitalized children inCroatia: a cross-sectional survey / G.
Palčevski, N. Skočibušić, V. VlahovićPalčevski // Eur J Clin Pharmacol. – 2012 Jul;68(7):1073-1077. doi:10.1007/s00228-012-1221-x. Epub 2012 Feb 4.209.Panayiotopoulos, C.P. Clinical Guide to Epileptic Syndromes and theirTreatment / C.P. Panayiotopoulos // Berlin: Springer. – 2010. – 578 p.210.Park, B.K. Idiosyncratic drug reactions: a mechanistic evaluation of riskfactors / B.K. Park, M. Pirmohamed, N.R. Kitteringham // Br. J. Clin. Pharmacol.– 1992. – Vol. 34.
– P. 377-395.211.Patsalos, P.N. Drug interactions with the newer antiepileptic drugs (AEDs).Part 2: Pharmacokinetic and pharmacodynamic interactions between AEDs anddrugs used to treat non-epilepsy disorders / P.N. Patsalos // Clin Pharmacokinet. –2013 Dec; 52(12):1045-1061.
doi: 10.1007/s40262-013-0088-z.212.Pedrós, C. Adverse drug reactions leading to urgent hospital admission in anelderly population: prevalence and main features / C. Pedrós, F. Formiga, X.Corbella, J.M. Arnau // Eur. J. Clin. Pharmacol. – 2016, Feb.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
